219 related articles for article (PubMed ID: 35917654)
1. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
[TBL] [Abstract][Full Text] [Related]
2. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Bishay K; Tandon P; Bourassa-Blanchette S; Laurie SA; McCurdy JD
Curr Oncol; 2020 Oct; 27(5):e486-e494. PubMed ID: 33173388
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
6. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
Wang DY; Ye F; Zhao S; Johnson DB
Oncoimmunology; 2017; 6(10):e1344805. PubMed ID: 29123955
[No Abstract] [Full Text] [Related]
7. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
Abu-Sbeih H; Ali FS; Wang Y
Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
[TBL] [Abstract][Full Text] [Related]
8. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB; Nielsen OH; Jacobsen S; Riis LB; Theile S; Bjerrum JT; Vilmann P; Johansen JS; Boisen MK; Eefsen RHL; Marie Svane I; Nielsen DL; Chen IM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096534
[TBL] [Abstract][Full Text] [Related]
9. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
10. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract][Full Text] [Related]
11. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors.
de Andrea CE; Perez-Gracia JL; Castanon E; Ponz-Sarvise M; Echeveste JI; Melero I; Sanmamed MF; Rodriguez-Ruiz ME
Oncoimmunology; 2020 May; 9(1):1760676. PubMed ID: 32934876
[TBL] [Abstract][Full Text] [Related]
12. Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis.
Ding M; Zhang X; Wang J; Gao F; Zheng X; Yuan J; Qi X
Dig Liver Dis; 2023 Dec; 55(12):1621-1631. PubMed ID: 36894390
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
14. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
Gong Z; Wang Y
JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor induced colitis: A nationwide population-based study.
Farha N; Alkhayyat M; Lindsey A; Mansoor E; Saleh MA
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101778. PubMed ID: 34332139
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.
Kaneoka A; Okada E; Sugino H; Saito-Sasaki N; Omoto D; Nakamura M
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204571
[TBL] [Abstract][Full Text] [Related]
19. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
[TBL] [Abstract][Full Text] [Related]
20. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
